Abbreviated ticagrelor based dual antiplatelet therapy in acute coronary syndrome: A systematic review and meta-analysis
Cardiovascular Revascularization Medicine · 2025
DOI: 10.1016/j.carrev.2024.09.005 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cardiovascular Revascularization Medicine, 2025. Verfasst von Wissam Harmouch und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: whharmou@utmb.edu. Hauptthemen laut MEDLINE: Ticagrelor, Acute Coronary Syndrome, Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Few randomized clinical trials have evaluated the safety and efficacy of abbreviated ticagrelor based dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS); however, these trials were underpowered to detect differences in hard clinical outcomes. METHODS: A systematic search of MEDLINE, Cochrane, and Scopus databases was performed through June 2024, for trials that compared abbreviated (≤3-months) versus standard 12-months ticagrelor based DAPT in ACS. The primary endpoint was all-cause mortality. Secondary endpoints included cardiovascular death, myocardial infarction, stent thrombosis, ischemic stroke, and major bleeding. Endpoints were measured at 12-months after DAPT initiation. Data were pooled using random-effects model. Effect measure utilized was risk ratio (RR). Heterogeneity was assessed via Chi-squared and Higgin's I2 test. RevMan 5.0 (Cochrane Collaboration, Oxford, United Kingdom) was utilized to perform statistical analysis. RESULTS: Five trials were included in this analysis with 21,407 patients assessed. ULTIMATE-DAPT, T-PASS, and GLOBAL LEADERS-ACS assessed 1-month DAPT duration while TICO and TWILIGHT-ACS assessed 3-months DAPT duration. The average age was 62.7 years and 22.7 % were women. ACS presentations included non-ST elevation myocardial infarction (40.1 %), unstable angina (35.2 %), and ST-segment elevation myocardial infarction (31.5 %). Abbreviated ticagrelor based DAPT was associated with lower risk of all-cause mortality (RR 0.78; 95 % Confidence Interval (CI) 0.62-0.98, I2 = 0 %) compared with standard duration DAPT. There was no difference between groups in cardiovascular death (RR 0.65; 95 % CI 0.41-1.03, I2 = 0 %), myocardial infarction (RR 1.04; 95 % CI 0.85-1.27, I2 = 0 %), stent thrombosis (RR 0.97; 95 % CI 0.64-1.45, I2 = 0 %), or ischemic stroke (RR 0.90; 95 % CI 0.62-1.30, I2 = 0 %). Abbreviated DAPT was associated with lower risk of major bleeding (RR 0.50; 95 % CI 0.38-0.66, I2 = 46 %). CONCLUSION: Our analysis includes the totality of randomized data evaluating the merits of abbreviated ticagrelor based DAPT after ACS. The salient study finding was the observed reduced risk of all-cause mortality and major bleeding with abbreviated DAPT approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: whharmou@utmb.edu.
- Division of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, USA.
- Department of Cardiology, Baylor College of Medicine and Michael E. DeBakey VA Medical Center, Houston, TX, USA.
- Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
- Division of Cardiology, Christus Good Shepherd Medical Center, Longview, TX, USA; Texas A&M School of Medicine, Bryan, TX, USA.
Zitieren
APA
Harmouch, W., Thakker, R., Khalid, M. U., Khalife, W., Kleiman, N., Rangasetty, U., Kayani, W. T., Jneid, H., Al-Hemyari, B., & Elbadawi, A. (2025). Abbreviated ticagrelor based dual antiplatelet therapy in acute coronary syndrome: A systematic review and meta-analysis. Cardiovascular Revascularization Medicine. https://doi.org/10.1016/j.carrev.2024.09.005
Vancouver
Harmouch W, Thakker R, Khalid MU, Khalife W, Kleiman N, Rangasetty U, et al. Abbreviated ticagrelor based dual antiplatelet therapy in acute coronary syndrome: A systematic review and meta-analysis. Cardiovascular Revascularization Medicine. 2025. doi:10.1016/j.carrev.2024.09.005
BibTeX
@article{Harmouch2025,
author = {Harmouch, Wissam and Thakker, Ravi and Khalid, Mirza Umair and Khalife, Wissam and Kleiman, Neal and Rangasetty, Umamahesh and Kayani, Waleed Tallat and Jneid, Hani and Al-Hemyari, Bashar and Elbadawi, Ayman},
title = {Abbreviated ticagrelor based dual antiplatelet therapy in acute coronary syndrome: A systematic review and meta-analysis},
journal = {Cardiovascular Revascularization Medicine},
year = {2025},
doi = {10.1016/j.carrev.2024.09.005}
}
EUVIMED